Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in patients with advanced hormone-positive breast cancer. The efficacy of this strategy is, however, limited by innate or acquired resistance mechanisms and its application to other tumor types is still uncertain. Here, through an integrative analysis of sensitivity and resistance mechanisms, we discuss the use of CDK4/6 inhibitors in combination with available targeted therapies, immunotherapy, or classical chemotherapy with the aim of improving future therapeutic uses of CDK4/6 inhibition in a variety of cancers.

中文翻译：

---

对CDK4 / 6抑制的敏感性和抗性机制

抑制细胞周期激酶CDK4和CDK6在晚期激素阳性乳腺癌患者中产生显着的治疗效果。然而，该策略的有效性受到先天性或后天性耐药机制的限制，其在其他肿瘤类型中的应用仍不确定。在这里，通过对敏感性和耐药性机制的综合分析，我们讨论了将CDK4 / 6抑制剂与可用的靶向疗法，免疫疗法或经典化学疗法结合使用的目的，目的是改善CDK4 / 6抑制剂在多种治疗中的未来治疗用途。癌症。